Marco Polo Pharmaceuticals and Biocortech Sign Licensing Agreement to Develop BC-19 in Treatment Resistant DepressionMarco Polo Pharmaceuticals has obtained rights to develop Biocortech’s BC-19 for treatment-resistant depression. The story was covered by Genetic Engineering News, a site that covers emerging technology and drug discovery news. Genetic Engineering News is a very relevant site for Marco Polo Pharmaceuticals as it will reach a large amount of key pharmaceutical industry personnel who may be interested in the development of BC-19.
CoverageGenetic Engineering News
RealWire Influence RatingReadership: 143,000